Dimensional Fund Advisors LP Purchases 95,600 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 4.9%, acquiring 95,600 additional shares, leading to ownership of over 2 million shares valued at approximately $129 million.
• Insider trading activity revealed that CEO Helen Torley sold 20,000 shares for $1.27 million, reducing her shareholding by 2.65% to 733,719 shares.
• Analysts have mixed views on Halozyme, with target price estimates ranging from $47.00 to $91.00, and a current consensus rating of "Hold" with a target price of $67.11.

Dimensional Fund Advisors LP increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,029,160 shares of the biopharmaceutical company's stock after buying an additional 95,600 shares during the quarter. Dimensional Fund Advisors LP owned 1.65% of Halozyme Therapeutics worth $129,478,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Isthmus Partners LLC increased its stake in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after buying an additional 169 shares during the period. OneDigital Investment Advisors LLC increased its stake in shares of Halozyme Therapeutics by 1.7% in the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after buying an additional 175 shares during the period. Park Place Capital Corp increased its stake in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares during the period. Xponance Inc. increased its stake in shares of Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock worth $1,190,000 after buying an additional 198 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on HALO shares. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Monday, August 18th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective on the stock. Finally, Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $67.11.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total value of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $46,598,493.69. The trade was a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 80,000 shares of company stock valued at $4,532,600. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Up 0.3%

Shares of NASDAQ:HALO traded up $0.25 during midday trading on Wednesday, reaching $73.18. The company's stock had a trading volume of 3,208,595 shares, compared to its average volume of 2,216,218. The firm has a 50 day moving average of $59.88 and a 200-day moving average of $59.05. The firm has a market capitalization of $8.56 billion, a P/E ratio of 16.75, a PEG ratio of 0.41 and a beta of 1.17. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $74.07.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.